Recursion Pharmaceuticals reported mixed Q2 results, with a net loss of $131.01 million and revenue down to $7.67 million. Despite progress in drug development and strategic partnerships, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results